NFKB1 and myeloproliferative disorder: This is in line with a recent report, which showed that inhibiting the NF-kB inflammatory pathway using a BET-inhibitor in combination with ruxolitinib was more effective than monotherapy in reducing myelofibrosis in a MPN mouse model7.